Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari. The post Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease appeared first on Investor's Business Daily.
Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.
The post Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
